Asymchem Laboratories (Tianjin) Co., Ltd. (FRA:7K90)

Market Cap	7.32B +79.7%
Revenue (ttm)	871.50M +16.6%
Net Income	139.61M +11.7%
EPS	0.39 +10.0%
Shares Out	n/a
PE Ratio	52.40
Forward PE	36.91
Dividend	0.17 (1.18%)
Ex-Dividend Date	Jun 25, 2026

Volume	n/a
Open	13.10
Previous Close	13.00
Day's Range	13.10 - 13.10
52-Week Range	7.45 - 14.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About FRA:7K90

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business. The company also engages in ke...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 10,617
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7K90

Financial Performance

In 2025, FRA:7K90's revenue was 6.67 billion, an increase of 14.91% compared to the previous year's 5.80 billion. Earnings were 1.13 billion, an increase of 19.35%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 20, 2026

Data Sources Report a data error